Robin Swartz
Vermögen: 1 Mio $ am 30.06.2026
Vermögen: 1 Mio $ am 30.06.2026
Robin Swartz is Chief Operating Officer & Business Officer at Voyager Therapeutics, Inc. since 2024.
Former roles include Director at Sanofi-Aventis, Inc., Vice President-Patient & Product Services at Genzyme Corp., and Vice President-Product Services at Genzyme Therapeutics Ltd. from 2018 to 2020.
Education includes undergraduate studies at Kenyon College.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 31.03.2026 | 286 488 ( 0,47 % ) | 1 Mio $ | 30.06.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| VOYAGER THERAPEUTICS, INC. | Geschäftsführer | 01.02.2022 |
| Unternehmen | Position | Ende |
|---|---|---|
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Corporate Officer/Principal | 01.06.2020 |
Sanofi-Aventis, Inc.
Sanofi-Aventis, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and wholesales pharmaceutical products | Direktor/Vorstandsmitglied | - |
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Kenyon College
Kenyon College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for patients affected by rare and debilitating diseases | Health Technology |
Voyager Therapeutics, Inc.
Voyager Therapeutics, Inc. BiotechnologyHealth Technology Develops gene therapies for fatal and debilitating diseases of the central nervous system | Health Technology |
Sanofi-Aventis, Inc.
Sanofi-Aventis, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and wholesales pharmaceutical products | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen